Brand Name

Dapzura

Generic Name
Daptomycin
View Brand Information
FDA approval date: February 22, 2017
Classification: Lipopeptide Antibacterial
Form: Injection

What is Dapzura (Daptomycin)?

DAPZURA RT is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections in adult and pediatric patients .

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

COMBAT-SAB: Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Summary: The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.

DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Summary: This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Staphylococcus Aureus Network Adaptive Platform Trial

Summary: The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).